



89bio to Participate in the 7th Annual Evercore HealthCONx Conference

November 26, 2024

SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.

The webcast of the fireside chat will be accessible in the investor section of [89bio's website](#). A replay of the webcast will be available for approximately 30 days following the conference.

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on [LinkedIn](#).

Investor Contact:

Annie Chang
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com

Media Contact:

Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com